Last reviewed · How we verify

Anakinra (r-metHuIL-1ra) — Competitive Intelligence Brief

Anakinra (r-metHuIL-1ra) (Anakinra (r-metHuIL-1ra)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-1 receptor antagonist. Area: Immunology.

marketed IL-1 receptor antagonist IL-1 receptor type I (IL-1RI) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anakinra (r-metHuIL-1ra) (Anakinra (r-metHuIL-1ra)) — Amgen. Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Anakinra (r-metHuIL-1ra) TARGET Anakinra (r-metHuIL-1ra) Amgen marketed IL-1 receptor antagonist IL-1 receptor type I (IL-1RI)
Anakinra (Kineret®) Anakinra (Kineret®) Monash Medical Centre phase 3 IL-1 receptor antagonist IL-1 receptor type I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-1 receptor antagonist class)

  1. Amgen · 2 drugs in this class
  2. Monash Medical Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anakinra (r-metHuIL-1ra) — Competitive Intelligence Brief. https://druglandscape.com/ci/anakinra-r-methuil-1ra. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: